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Abstract
Background:  Ventilator-associated  pneumonia  (VAP)  is  the  most  common  nosocomial
infection  acquired  by  patients  in  the  intensive  care  unit  (ICU).  However,  the  eco-
nomic  effects  of  such  infections  remain  unclear  particularly  in  developing  countries.
Methods:  Patients  who  were  mechanically  ventilated  for  more  than  48  h  in  the
ICU  were  studied  for  the  occurrence  of  VAP.  Total  drug  costs  and  hospital  costs
were  noted,  and  attributable  costs  were  calculated  after  adjusting  for  potential
confounders.
Results:  Ninety-ﬁve  (38%)  patients  who  were  ventilated  for  more  than  48  h devel-
oped  VAP,  which  resulted  in  an  incidence  of  40.1  VAP  infections/1000  mechanical
ventilation  days.  The  patients  with  VAP  experienced  signiﬁcantly  longer  hospital
stay  [21  (IQ  =  14—33)  days  versus  11  (IQ  = 6—18)  days,  P  <  0.0001)]  and  incurred
greater  hospital  costs  [USD  $6250.92  (IQ  =  3525.39—9667.57)  versus  $2598.84
(IQ  =  1644.33—4477.65),  P  <  0.0001].  Multiple  regression  analysis  revealed  that  the
cost-driving  factors  in  our  study  population  were  the  occurrence  of  VAP  infections
(P  <  0.0001)  and  the  duration  of  hospital  stay  (P  <  0.0001).  The  attributable  cost  of
VAP  infection  was  calculated  to  be  USD  $5200  (95%  CI  =  3245—7152).
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e  that  VAP  signiﬁcantly  increases  the  costs  of  treatment  in
ountries.  This  study  highlights  the  need  to  implement  urgent
incidence  of  this  disease  in  ICUs.
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parity  value  of  the  Indian  rupee  for  the  year  2011  (1
USD $ =  47.9229  INR;  Reserve  Bank  of  India  exchange
rates available  from  URL:  http://www.rbi.org.in/Conclusion:  We  conclud
low-income  developing  c
measures  to  reduce  the  
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Introduction
Ventilator-associated  pneumonia  (VAP)  is  the  lead-
ing cause  of  nosocomial  infection  in  intensive
care unit  (ICU)  patients.  While  the  international
nosocomial infection  control  consortium  (INICC)
data suggests  that  the  incidence  of  VAP  is  as
high as  13.6/1000  mechanical  ventilator  (MV)  days
[1],  the  occurrence  of  VAP  in  Asian  countries  is
much  higher  and  ranges  from  3.5  to  46  infec-
tions/1000 MV  days  [2]. In  US  hospitals,  VAP  is  the
second  most  costly  nosocomial  infection  at  $40,144
(95% CI,  $36,286—44,220)  [3]. Similarly,  in  develop-
ing countries,  the  total  costs  attributed  to  patients
with VAP  infections  are  nearly  ﬁve-fold  higher  than
those of  other  patients  [4]. Given  the  paucity  of
available  data  from  the  Asian  subcontinent  and
the potential  signiﬁcance  of  the  economic  burden
imposed by  this  common  nosocomial  infection,  we
conducted  a  prospective  audit  of  all  VAP  infections
that were  acquired  in  our  ICU.  The  primary  objec-
tive of  this  audit  was  to  study  the  incidence  and  the
attributable  costs  of  VAP  infections.  Additionally,
we sought  to  study  the  microbiological  charac-
teristics of  these  infections  and  the  outcomes  of
patients who  developed  VAP  infections.
Materials and methods
Setting and subjects
We  conducted  this  prospective  observational  study
in an  adult,  tertiary-level  ICU  in  northern  India  over
one year  (October  1,  2010  to  September  30,  2011).
Our ICU  is  a  mixed  medical-surgical,  tertiary  level
ICU with  approximately  900—1000  admissions  per
year. After  receiving  approval  from  the  institutional
ethics review  board,  we  studied  all  of  the  adult
patients who  were  intubated  and  mechanically  ven-
tilated for  more  than  48  h.  We  excluded  patients
who were  already  intubated  and  those  who  were
on mechanical  ventilation  for  more  than  12  h prior
to ICU  admission.Data collection
After  admission  into  the  ICU,  we  noted  the  basic
demographic  details,  including  age,  gender,  Acute
s
a
yhysiology  and  Chronic  Health  Evaluation  (APACHE
I) score  at  admission,  category  of  admission,
iagnosis at  admission,  and  the  presence  of  any
omorbid  illnesses,  of  all  of  the  included  patients.
e also  noted  any  histories  of  addictions,  including
moking, alcohol  intake,  and  the  use  of  narcotic
r immunosuppressive  drugs.  All  of  the  included
atients were  evaluated  daily  for  clinical  signs
f VAP  using  the  Centers  for  Disease  Control  and
revention  (CDC)  criteria.  The  clinical  pulmonary
nfection score  (CPIS)  was  calculated  on  the  day
f clinical  suspicion  of  VAP  and  on  the  third  day
fter that.  CPIS  scores  ≥6  were  considered  to  be
igniﬁcant. For  all  patients  with  suspected  VAP,  we
ollected respiratory  samples  by  blind  deep  endo-
racheal  aspiration  and  followed  the  culture  results
o note  the  patterns  of  infection  and  the  resistance
haracteristics of  the  isolated  organisms.
We  also  followed  up  all  patients  to  note  their
utcomes (i.e.,  discharge  or  death)  and  the  total
urations  of  their  stays  in  the  ICU  and  the  hospital.
he ﬁnal  bills  of  patients  were  accessed  to  study
he drug  costs  and  total  hospital  costs  that  were
ncurred.
erminology
entilator-associated  pneumonia  (VAP)  was  deﬁned
y the  novel  onset  of  pneumonia  in  ventilated
atients over  the  period  of  48  h  from  the  initiation
f mechanical  ventilation  until  48  h  after  extuba-
ion.
Early  onset  VAP  was  deﬁned  as  VAP  that  devel-
ped in  ventilated  patients  within  the  ﬁrst  four  days
<4 days)  of  mechanical  ventilation.
Late onset  VAP  was  deﬁned  as  VAP  that  devel-
ped in  ventilated  patients  from  the  ﬁfth  day  (≥5
ays) of  mechanical  ventilation.
Conversion  rates:  all  costs  were  calculated  in
ndian rupees  (INR)  and  were  then  converted  to
S dollars  (USD)  using  the  mean  purchasing  powercripts/PublicationsView.aspx?id=14503  were
ccessed on  30/12/2013)  [5].
Calculation  of  costs  per  life  saved  and  per  life-
ear saved:  The  calculations  of  the  costs  per  life
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saved  and  per  life-year  saved  for  VAP  are  shown  in
the Appendix.  To  calculate  the  per  life-year  saved,
ﬁgures  for  the  life  expectancy  at  birth  in  India
(63 years  for  males,  66  years  for  females)  were
obtained from  the  2011  World  Health  Report  [6].
Statistical analyses
The  statistical  measures  used  included  frequencies,
descriptive statistics,  Mann—Whitney  U-tests  and
multiple linear  regression  analysis.  To  normalize
the distribution  of  the  total  cost,  we  used  the  nat-
ural log  transformation.  The  VAP  estimates  (with
95% conﬁdence  intervals)  according  to  mechan-
ical ventilation  days,  total  ICU  days  and  total
hospital days  were  calculated  via  multiple  lin-
ear regression  models  after  adjustments  for  age,
APACHE  II  score  and  the  type  of  admission.  We
calculated  the  attributable  cost  using  a  multivari-
able  linear  regression  model.  Regression  equations
were  calculated  for  both  patients  with  and  with-
out VAP  infections.  The  regression  model  for  the
VAP patients  was  adjusted  for  age,  APACHE  II  score,
length of  stay  in  the  ICU,  length  of  inpatient  stay
and the  duration  of  mechanical  ventilation  before
VAP developed.  The  second  model  for  the  non-VAP
patients was  adjusted  for  age,  APACHE  II,  length  of
ICU stay  and  duration  of  inpatient  stay.  The  results
were back  transformed  by  taking  the  exponent.  The
attributable  cost  was  calculated  by  subtracting  the
costs calculated  via  these  two  models.  The  statis-
tical  analyses  were  performed  with  SPSS  version  21
(IBM Corp.;  Armonk,  NY).
Results
Demographic characteristics
During  the  study  period,  845  patients  were  admit-
ted to  the  ICU,  and  250  of  these  patients  met
the inclusion  criteria  (Fig.  1).  The  majority  of  the
845 patients 
screened 
250 included 
(MV > 48 hrs)
95 VAP 
(38%) 
155 non VAP 
(62 %) 
65 non survivors 
(68%) 
30 survivors  
(32%) 
94 non survivors 
(60%) 
61 survivors  
(40%) 
Fig.  1  Flow  chart  illustrating  the  screening  and  selection
processes  and  the  outcomes  of  the  studied  patients.
Fig.  2  Microbiological  organisms  isolated  from  the
patients  with  VAP  infections  (with  percentages).  Gram-
negative  organisms  caused  a  large  majority  of  the  VAP
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Anfections,  and  Acinetobacter  was  the  single  most  fre-
uently  isolated  species.
atients  (149,  59.6%)  were  males,  and  the  mean
atient  age  was  53.60  (±SD  18.03)  years.  The  aver-
ge APACHE  II score  at  admission  was  20.74  (±SD
.75),  and  the  majority  of  patients  (192,  76.8%)
ere  admitted  under  the  medical  category.
A total  of  95  (38%)  patients  developed  VAP  dur-
ng the  study  period,  which  resulted  in  an  incidence
f 40.1  episodes  of  infection/1000  mechanical  ven-
ilation (MV)  days.  The  device  utilization  ratio  was
.85. While  there  were  no  associations  between  VAP
nd any  comorbid  illnesses  (e.g.,  such  as  diabetes
ellitus and  hypertension),  the  male  patients  were
ound to  be  at  a  greater  risk  for  developing  VAP
nfections  (Table  1).  The  majority  of  VAP  episodes
65 patients,  69%)  were  late  infections  (i.e.,  infec-
ions acquired  after  5  days  of  ventilation).
icrobiological characteristics and
esistance patterns
he  majority  of  the  VAP  cases  (87.15%)  were
aused by  Gram-negative  organisms  such  as  Acine-
obacter  (58  isolates,  53.2%),  Klebsiella  (15.6%)
nd Pseudomonas  species  (12.8%).  Cultures  yielded
ram-positive  organisms  in  only  ﬁve  instances,
nd these  organisms  included  methicillin-resistant
taphylococcus  aureus  (MRSA)  in  four  patients
Fig.  2). Ventilator-associated  pneumonia  was
aused by  multidrug-resistant  (MDR)  organisms  in
6 (27.3%)  patients.  There  were  high  proportions  of
xtended spectrum   lactamase  (ESBL)-producing
trains among  the  Klebsiella  species  (13  isolates,
6.5%) and  the  Escherichia  coli  (5  isolates,  55.55%)
trains.  While  all  strains  of  Acinetobacter  were  MDR
rganisms,  25  of  these  isolates  (43.1%)  were  resis-
ant to  even  the  carbapenem  group  of  antibiotics.
 signiﬁcant  number  of  Klebsiella  (12  isolates,  70%)
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Table  1  Univariate  analysis  of  the  demographic  characteristics  between  patients  with  VAP  and  without  VAP.
Characteristics  VAPa (n  =  95)  non-VAP  (n  = 155)  Pb value
Age  (years)
(mean  ±  SDc)
55.49  ±  17.45  52.43  ±  18.40  0.19
Gender
(Males)
65  (68%)  84  (54%)  0.03
APACHE  II
(mean  ±  SDc)
21.41  ±  6.73  20.32  ±  6.75  0.21
Type  of  admission
(medical/surgical)
72/23  120/35  0.18
Co-morbidities
Diabetes  33  (35%)  56  (36%)  0.82
Hypertension  50  (53%)  71  (46%)  0.29
IHDd 27  (28%)  33  (21%)  0.20
Obesity  13  (14%)  19  (12%)  0.74
COPDe 17  (18%)  18  (12%)  0.16
Smoking  20  (21%)  21  (14%)  0.12
Alcoholism  22  (23%)  27  (17%)  0.26
Steroid  use  11  (12%)  18  (12%)  0.99
a VAP — ventilator associated pneumonia.
b P value < 0.05 was considered signiﬁcant.
c SD — standard deviation.
b
(
Cd IHD — ischemic heart disease.
e COPD — chronic obstructive heart disease.
and  Pseudomonas  (4  isolates,  28.5%)  isolates  also
exhibited  resistance  to  carbapenems.
OutcomesThe  crude  in-hospital  mortality  rates  were  similar
between  the  VAP  and  non-VAP  patients.  However,
the patients  with  VAP  infections  were  mechani-
cally ventilated  for  longer  durations  and  stayed  in
W
m
a
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Table  2  Univariate  analysis  of  the  outcome  variables  betw
Variables VAPa
n  =  95  
Median  (IQc) 
APACHE  IId 22  (15—26)  
Total  MVe days  12  (8—19)  
LOSf
ICU  13  (10—21)  
Hospital  21  (14—33)  
Costs  incurred
Total  (US$) 6250.92  
(3525.39—9667.57)  
Drugs  (US$) 2587.49  
(1577.18—4257.15)
Mortality  65  (68.4%)
a VAP — ventilator associated pneumonia.
b P value < 0.05 was considered signiﬁcant (written in bold).
c IQ — interquartile range.
d APACHE II — Acute Physiology and Chronic Health Evaluation sc
e MV — mechanical ventilation.
f LOS — length of stay.oth  the  ICU  and  the  hospital  for  longer  durations
P <  0.0001;  Table  2).
osts incurrede  found  that  the  total  costs  incurred  for  treat-
ent and  medications  were  signiﬁcantly  higher
mong the  VAP  patients  than  the  patients  with-
ut VAP  (P  < 0.0001;  Table  2).  When  we  further
een  patients  with  VAP  versus  non-VAP.
non  VAP  Pb value
n  =  155
Median  (IQc)
21  (14—26)  0.26
4  (4—7)  <  0.0001
6  (4—8)  <  0.0001
11  (6—18)  <0.0001
2598.84
(1644.33—4477.65)  <  0.0001
930.12
(482.27—2023.08)  <  0.0001
95  (61.3%)  0.200
ore.
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ars  represent  the  95%  conﬁdence  intervals.
tudied  the  cost  differences  between  the  patients
n each  group  who  survived  to  hospital  discharge,
e found  that  the  cost  difference  between  the
AP and  non-VAP  patients  persisted.  The  cost  per
ife saved  was  calculated  to  be  USD  $28,030.62,
nd the  cost  per  life-year  saved  was  USD  $5143.23
Appendix A).
The  multivariate  analysis  revealed  that  the
AP patients  required  11  additional  days  on
echanical  ventilation  (P  <  0.0001),  10  additional
ays in  the  ICU  (P  <  0.0001)  and  four  additional
otal hospital  days  (P  = 0.21)  after  controlling
or age,  category  of  admission,  and  severity
f illness  based  on  the  APACHE  II  scores.  The
ttributable cost  of  VAP  infection  was  calculated
o be  USD  $5200  (95%  CI  =  3245—7152;  Fig.  3).
ultiple regression  analysis  revealed  that  the  cost-
riving factors  in  our  study  population  in  the  ICU
ere the  presence  of  VAP  infection  (P  <  0.0001)
nd the  length  of  hospital  stay  (P  <  0.0001;
able  3).
d
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Table  3  Multiple  regression  analysis  to  determine  the  cost
Variables  Ba (95%  CIb)  
Age  0.002  (−0.002  to  0.006)  
Total  days  0.006  (−0.011  to  0.024)  
Length  of  ICU  stay  0.013  (−0.004  to  0.029)  
Length  of  hospital  stay  0.02  (0.015—0.025)  
APACHE  II  score  0.006  (−0.005  to  0.016)  
VAP  0.338  (0.162—0.513)  
a Regression coefﬁcient.
b Conﬁdence interval.
c P value < 0.05 was considered signiﬁcant (written in bold).l  costs  between  the  VAP  and  non-VAP  patients.  The  error
iscussion
ndemic proportions
entilator-associated  pneumonia  (VAP)  has  signiﬁ-
ant effects  on  morbidity,  mortality  and  the  costs
ncurred by  patients  hospitalized  in  ICUs  [7—9].
ccording  to  the  National  Healthcare  Safety  Net-
ork (NHSN)  report  data  summary  for  2012,  the
ates of  all  device-associated  infections,  including
AP, are  higher  in  major  teaching  locations  than  in
heir non-teaching  counterparts,  and  critical  burn
are locations  have  the  highest  rates  of  device-
ssociated infections  [10].
Our study  revealed  high  VAP  rates  among
atients who  were  mechanically  ventilated  in  the
ntensive care  unit;  i.e.,  the  rate  of  infection  was
7.5%, and  there  were  40.1  VAP  episodes/1000  MV
ays. The  average  VAP  rates  reported  in  other
ndian studies  range  from  8.9  to  46  VAP  episodes  per
000 MV  days  [11]. The  INICC  data  from  studies  of
 driving  factors  of  VAP  infections  in  the  ICU.
Exponentiated  Ba (95%  CIb) Pc value
1.002  (0.998—1.006)  0.25
1.006  (0.989—1.024)  0.49
1.013  (0.996—1.029)  0.14
1.020  (1.015—1.025)  <0.0001
1.006  (0.995—1.016)  0.30
1.402  (1.175—1.670)  <0.0001
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nosocomial  infections  in  eight  developing  countries
over 4  years,  revealed  that  VAP  infections,  with
an overall  incidence  of  41.5%  or  24.1  cases/1000
mechanical  ventilation  days,  pose  the  greatest
challenge for  treatment  among  all  HCAIs  [12]. Our
study found  no  signiﬁcant  associations  between
VAP and  any  of  the  demographic  factors  that  were
studied  with  the  exception  of  male  gender.  In pre-
vious studies,  the  reported  risk  factors  for  VAP
infections have  included,  male  sex,  elderly  age,
higher APACHE  II  scores,  prolonged  antibiotic  usage,
immunosuppression,  reintubation,  etc.  [2].
Microbiological spectrum
Gram-negative  pathogens  were  the  predominant
cause of  VAP  infections  in  our  study,  and  this
ﬁnding is similar  to  those  of  other  Asian  studies
[2,11,12].  A  recent  report  presented  by  a  panel  of
experts from  10  Asian  countries  suggested  that  the
prevalence  of  multidrug-resistant  pathogens  is  ris-
ing in  Asian  countries  and  that  the  Acinetobacter
baumannii—calcoaceticus  complex  is emerging  as  a
major pathogen  in  the  majority  of  these  ICUs  [2].
Another Indian  study  reported  that  the  majority  of
VAP cases  in  tertiary-level  ICUs  are  caused  by  Gram-
negative  bacteria  (80.9%)  such  as  Pseudomonas
aeruginosa (21.3%)  and  Acinetobacter  baumannii
(21.3%) [11].
We  also  noted  that  a  high  proportion  of  our  VAP
infections were  caused  by  MDR  pathogens,  including
carbapenem-resistant,  Gram-negative  organisms,
which  is  cause  for  serious  concern.  ‘‘Multidrug-
resistant’’ (MDR)  refers  to  bacterial  pathogens,
such as  Pseudomonas  species,  Acinetobacter
species,  MRSA,  and  enteric  Gram-negative  bacilli,
that express  ESBL  and  AmpC  -lactamases  and
characteristically  exhibit  high  levels  of  antibiotic
resistance [13,14]. The  INICC  data  from  eight  devel-
oping countries  reported  that  Enterobacteriaceae
species  (26%,  with  58%  resistant  to  ceftriaxone)
was the  most  commonly  identiﬁed  isolate  among
VAP infections  followed  by  P.  aeruginosa, S.  aureus
(77.5%  of  which  were  OXA-resistant  isolates)  and
Acinetobacter  species  (with  52.4%  of  the  iso-
lates resistant  to  carbapenems)  [12].  A  nine-month
prospective study  from  an  Indian  tertiary  care
hospital reported  a  45.4%  incidence  of  VAP  that
included  MDR  Acinetobacter  infections  (48%)  and
MDR Pseudomonas  infections  (27%)  [15].
Effects on outcomesThe  mortality  rates  were  comparable  between  the
VAP and  non-VAP  patients  in  our  center.  However,
other studies  have  reported  signiﬁcantly  higher
r
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ortality  rates  among  patients  who  develop  VAP
nfections  [3]. The  crude  mortality  rate  in  our  hos-
ital was  higher  than  that  reported  in  some  Indian
tudies  (16—37%)  [9,16], while  the  INICC  data  for
eveloping  countries  reported  a crude  mortality
ates of  44.9%  among  patients  who  developed  VAP
12].
Among  the  patients  who  developed  VAP  infec-
ions, the  length  of  stay  in  the  ICU  was  nearly
hree-fold greater,  and  the  total  hospital  stay  was
ouble the  duration  of  the  patients  who  did  not
evelop  VAP  infections.  These  ﬁndings  conﬁrm  the
esults of  numerous  other  studies  that  have  shown
hat the  development  of  nosocomial  pneumonia
eads to  prolonged  hospital  stays  [17—20].  Among
ur patients,  the  high  incidence  of  MDR  organisms
hat caused  VAP  infections  probably  contributed  to
he prolonged  stays  because  these  infections  took
onger to  treat  and  generally  resulted  in  poorer
ourses in  the  ICU.
conomic effect
n  our  study,  the  attributable  cost  of  VAP  infection,
fter adjusting  for  the  variables  of  age,  APACHE
I score,  length  of  ICU  stay,  length  of inpatient
tay and  the  duration  of  mechanical  ventilation
rior to  the  development  of  VAP,  was  INR  rupees
49,199 (95%  CI:  155,510—342,745)  or  USD  $5200
95% CI  = 3245—7152).  This  cost  was  the  result  of
igniﬁcantly  higher  total  medication  costs,  higher
rug costs,  and  increases  in  the  length  of  ICU  stays.
omparisons  across  studies  of  the  economics  of  VAP
nfections  are  difﬁcult  because  various  studies  have
sed different  cost  calculation  methods.  Although
he actual  cost  numbers  vary  widely,  increases  in
ospital costs  that  are  attributable  to  VAP  infec-
ions have  been  nearly  unanimously  reported  in
he relevant  studies  [21—26]. Although  no  com-
arative data  from  India  are  available,  a Turkish
tudy reported  that  the  daily  costs  of  patients  with
AP infections  are  three-fold  greater  than  those  of
heir counterparts  without  VAP  and  that  the  mean
CU stay  length  is  approximately  four-fold  longer
22]. In  a  large  matched  cohort  study  of  88,689
atients, the  VAP  patients  were  found  to  a  higher
verall  length  of  stay  (21.8  versus  10.3  days)  and
 higher  mean  hospitalization  cost  ($99,598  versus
59,770)  compared  to  patients  who  did  not  develop
AP infections  [25].  A  systematic  review  of  the  clin-
cal and  economic  consequences  of  VAP  infections
evealed that  between  10%  and  20%  of  patients  who
eceiving  more  than  48  h of  mechanical  ventilation
evelop VAP  infections,  and  these  patients  have
igniﬁcantly  longer  ICU  stay  lengths  and  while  incur-
ing more  than  USD  $10,019  in  additional  hospital
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yncidence  and  attributable  costs  of  ventilator-assoc
osts  [26].  Our  study  also  showed  that,  in  addi-
ion to  VAP,  the  length  of  hospital  stay  was  the
rimary cost-driving  factor  among  ICU  patients.
everal other  studies  have  also  conﬁrmed  this  ﬁnd-
ng [27—29].
trengths and limitations
his  study  is  the  ﬁrst  hospital-based  cost  anal-
sis of  VAP  infections  from  India  and  might
eﬂect the  effects  of  the  costs  of  VAP  infec-
ions in  similar  resource-poor  countries.  Due  to
he signiﬁcant  expenses  incurred  by  this  common
osocomial infection  among  critically  ill  patients,
 cost  analysis  such  as  this  one  is  called  for.
his study  might  have  value  for  individual  insti-
utions that  are  concerned  with  the  escalating
osts of  healthcare-associated  infections  and  are
harged with  the  responsibility  of  reducing  health-
are costs.  Cost  analyses  of  this  type  provide
aluable information  about  the  economic  burden
f this  disease  and  enable  the  study  of  the  efﬁcacy
f infection  control  measures.  The  other  notable
trengths of  our  study  were  that  it  was  prospec-
ively conducted  from  the  clinician’s  perspective,
nd the  diagnoses  of  VAP  were  based  on  clini-
al criteria  and  supplemented  with  microbiological
esults. The  limitations  of  our  study  were  that
he respiratory  samples  were  obtained  by  blind
ndotracheal aspiration,  and  quantitative  cultures
ould not  be  performed  on  the  aspirates  due  to
esource  limitations.  These  limitations  might  have
ed to  an  over  estimation  of  the  incidence  of
nfection.
Our study  highlights  the  need  for  urgent  infection
ontrol and  planning  and  the  need  for  multidis-
iplinary team  participation  to  combat  VAP  that
ncludes  the  implementation  of  measures  such  as
ducation,  increased  awareness  of  hand  hygiene
easures, reductions  in  the  durations  of  mechan-
cal ventilation  and  the  use  of  VAP  bundles.  All  of
hese measures  have  been  proven  to  reduce  the  risk
f VAP  infection  [30,31].  The  INICC  data  regarding
AP infections  in  44  adult  intensive  care  units  from
4 developing  countries  revealed  that  the  imple-
entation of  a  multidimensional  approach  that
ncludes  a  set  infection  control  interventions,  edu-
ation outcome  surveillance,  process  surveillance,
eedback regarding  ventilator-associated  pneumo-
ia rates  and  performance  feedback  regarding
nfection-control  practices  resulted  in  a  55.83%
ecrease in  the  rate  of  ventilator-associated  pneu-
onia from  22.0  per  1000  mechanical  ventilator
ays to  17.2  per  1000  mechanical  ventilator  days
32].  More  speciﬁcally,  data  from  21  ICUs  across
0 Indian  cities  revealed  a  38%  decrease  in  thed  pneumonia  (VAP)  133
AP  rates  from  17.43/1000  mechanical  venti-
ator days  to  10.81/1000  mechanical  ventilator
ays (relative  risk  0.62,  95%  conﬁdence  inter-
al 0.5—0.78,  P  =  0.0001)  during  the  same  study
eriod based  on  the  same  interventional  measures
33].
onclusion
e  conclude  that  VAP  occurs  in  a considerable
roportion  of  patients  who  undergo  mechanical
entilation and  is  associated  with  excess  costs,
ubstantial  morbidity  and  prolonged  hospitaliza-
ion. Considering  the  economic  effects  of  VAP
nd the  effects  of  VAP  on  the  health-care  sys-
em, we  strongly  recommend  the  introduction  of
ppropriate  interventional  measures  prevent  the
evelopment  of  VAP.
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ppendix A.
1)  Calculation  of  the  cost  per  life  saved:  There
ere 30  survivors  of  ventilator-associated  pneumo-
ia (VAP)  in  the  ICU  during  the  study  period.
Total cost  incurred  by  all  VAP  patients  =  USD
840,918.56
Cost per  life  saved  =  840,918.56/30  =  USD
28,030.62
(2) Calculation  of  the  cost  per  life-year  saved:
Male deaths  from  VAP:  n =  44,  mean  age  58.39
ears.
Mean life  expectancy  =  63  years  (The  World  Health
Report  2011)  [14].
Life-years  expected  =  63  ×  44  = 2772.
Life-years  lived  =  58.39  ×  44  =  2569.
Life-year  lost  =  2772—2569  =  203.
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Female  deaths  from  VAP:  n  =  21,  mean
age =  58.81  years.
Mean  life  expectancy  =  66  years  (The  World  Health
Report 2011)  [14].
Life-year  expected  =  66  ×  21  =  1386.
Life-years  lived=  58.81  × 21  =  1235.
Life-years lost  =  1386—1235  =  151.
Total life-years  lost  = 203  + 151  =  354.
Mean life-years  lost  for  all  patients  who  died
from VAP  in  the  ICU  = 354/65  = 5.45  years.
Cost per  life-year  of  VAP  infection  =  USD
$28,030.63/5.45  =  USD  $5143.23.
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